

AD _____

(Leave blank)

Award Number: W81XWH-11-1-0015

TITLE: Identification of Small Molecules Targeting the Posttranscriptional Control of ERG Expression

PRINCIPAL INVESTIGATOR: Yijun Zhu, MD

CONTRACTING ORGANIZATION:
Northwestern University
Evanston, IL 60208

REPORT DATE: October 2012

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

- ☒ Approved for public release; distribution unlimited
- ☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) October 2012		2. REPORT TYPE Final		3. DATES COVERED (From - To) From 03-08-March2011-07 September2012	
4. TITLE AND SUBTITLE Identification of Small Molecules Targeting the Posttranscriptional Control of ERG Expression				5a. CONTRACT NUMBER W81XWH-11-1-0015	
				5b. GRANT NUMBER-W81XWH-11-1-0015	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yijun Zhu Cqi451@northwestern.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northwestern University Evanston, IL 60208				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materials Command Fort Detrick, Maryland 21702-				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited.					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT TMPRSS2-ERG translocation is involved in about 60% of prostate cancers. The translocation leads to overexpression of ERG which promotes cell proliferation and abrogates prostate epithelial differentiation. Suppression of ERG expression represents a major way to treat prostate cancers. However, there are no effective means to inhibit ERG expression. Although siRNA can deplete ERG expression, the big challenge is to deliver siRNA into prostate cancer cells. The mRNA stability, translation efficiency and protein stability of ERG are under strict control to maintain the ERG protein level. Here we report the establishment of a cell line which can be used to identify small molecules which inhibit ERG expression by targeting its post-transcriptional process. Using this cell line, we performed high-throughput screening and identified Gambogic acid which suppresses ERG expression in ERG-overexpressing prostate cancer cells.					
15. SUBJECT TERMS Prostate carcinoma; ERG; small molecules, post-transcriptional.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unlimited	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON Yijun Zhu
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			19b. TELEPHONE NUMBER (include area code) 3125033113

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	2
Key Research Accomplishments.....	4
Reportable Outcomes.....	5
Conclusion.....	6
References.....	7
Appendices.....	8

INTRODUCTION

TMPRSS2-ERG translocation is involved in about 60% of prostate cancers. The translocation leads to overexpression of ERG which promotes cell proliferation and abrogates prostate epithelial differentiation. Suppression of ERG expression represents a major way to treat prostate cancers. However, we do not have effective means to inhibit ERG expression. Although siRNA can deplete ERG expression, the big challenge is to deliver siRNA into prostate cancer cells. The mRNA stability, translation efficiency and protein stability of ERG are under strict control to maintain the ERG protein level. The objectives of this proposed research are to identify small molecules which inhibit the expression of ERG by targeting its post-transcriptional process.

BODY

Task 1. Establish a prostate cancer reporter cell line for screening.

We at first generated a vector which expresses a transcript composed of coding region for luciferase and ERG fusion protein and the 3'UTR of ERG (Fig. 1) with pCDNA3.1. The inclusion of the reporter luciferase cDNA into ERG cDNA allowed the identification of small molecules which affect ERG mRNA stability and translation efficiency. By using the in-frame fusion of luciferase with ERG cDNA, chemicals affecting ERG protein stability can also be identified. To establish a cell line expressing luciferase-ERG fusion protein, the vector along pRL-CMV-Rluc expressing Renilla luciferase gene was transfected into LNCaP cells. The pRL-CMV-Rluc served as an internal control. The cells were treated with G418. Individual clones were isolated, expanded, and examined for the expression of two different luciferases. A clone expressing both Firefly luciferase and Renilla luciferase was selected for further studies.





Fig. 1. The structure of vector expressing Luciferase and ERG fusion protein.

Task 2. Perform high throughput screening for small molecules.

The screening was performed in our university core facility. Ten thousand reporter cells were seeded per well in 384 well-plates and were treated with the individual chemical at 10 μ M for 24 h. The dual luciferase activities were measured. The ratio of Firefly to Renilla luciferase activity was calculated. The ratio value decreased to 40% of the value from the control cells were considered as a hit and selected for further analysis. From a total of 5 hits, we identified Gambogic acid which consistently suppressed Firefly luciferase activity compared with Renilla luciferase activity (Fig. 2a). We confirmed that Gambogic acid decreased the protein level of ERG-Luciferase fusion protein (Fig. 2b).

Fig. 2. (a). Gambogic acid suppresses the activity of Firefly luciferase. Cells were treated with control vehicle or Gambogic acid (GAM) for 24h. The Firefly and Renilla luciferase activities were measured and the ratios were calculated. (b). Gambogic acid (GAM) decreased the protein level of ERG-Luciferase (ERG-Luc) fusion protein, as shown by Western blot.



Task 3. Test if the identified molecules can inhibit the proliferation of prostate cancers by inhibiting ERG protein expression.

VCaP cells which carry TMPRSS2-ERG translocation were treated with Gambogic acid or control vehicle for 48h. Real time RT-PCR for ERG revealed that ERG mRNA was not changed (Fig. 3a), indicating that the compound does not affect the ERG mRNA stability. However, Western blot revealed that ERG protein was reduced by the treatment (Fig. 3b). Pulse-chase experiment revealed that ERG protein is less stable when treated with Gambogic acid (Fig. 3c), indicating that the compound acts through down-regulating the protein stability.




Fig. 3. a). ERG mRNA levels are not affected by the treatment of Gambogic acid (GAM), as revealed by real-time RT-PCR. b). ERG protein is reduced by the treatment of Gambogic acid, as shown by Western blot. c). ERG protein is less stable with the treatment of Gambogic acid (GAM), as revealed by pulse-chase analysis. S^{35} labeled ERG was precipitated by anti-ERG at several time points (0, 6h, 12h) following the labeling with S^{35} for 30 minutes.

KEY RESEARCH ACCOMPLISHMENTS

- * We report the establishment of a cell line which can be used to identify small molecules inhibiting ERG expression.
- * We performed high-throughput screening and identified Gambogic acid which suppresses ERG-Luc expression.
- * We found that Gambogic acid inhibits the expression of ERG in ERG-overexpressing prostate cancer cells.

REPORTABLE OUTCOMES

None

CONCLUSIONS

We report the establishment of a cell line which can be used to identify small molecules which inhibit ERG expression. Using this cell line, we performed high-throughput screening and identified Gambogic acid which suppresses ERG-Luc fusion protein expression. We found that Gambogic acid can suppress ERG expression in ERG overexpressing prostate cancer cells.

REFERENCES

None

APPENDICES

None.